Asia Pacific Breast Cancer Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), and Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies)
The Asia Pacific breast cancer therapeutics market was valued at US$ 6,986.37 million in 2022 and is expected to reach US$ 15,819.83 million by 2030; it is estimated to grow at a CAGR of 10.8% from 2022 to 2030.
Launch of Several Diagnostics and Screening Programs Fuels the Asia Pacific Breast Cancer Therapeutics Market
Advancements in personalized medicine, immunotherapy, combination therapies, drug delivery systems, liquid biopsies, AI, and patient-centric approaches are expected to shape the future of breast cancer treatment. These trends aim to improve treatment outcomes, reduce side effects, and enhance breast cancer patients overall quality of life.
Early disease detection plays a major role in improving patient outcomes and survival rates. Various organizations and healthcare providers are implementing screening programs to detect breast cancer at an initial stage when it is more treatable. The World Health Organization released a new Global Breast Cancer Initiative Framework in February 2013 that serves as a plan for fulfilling the goal of saving 2.5 million people from breast cancer by 2040. To achieve this, the new Framework, unveiled ahead of the World Cancer Day campaign, urges nations to follow the three pillars of health promotion for early detection, prompt diagnosis, and thorough management of breast cancer. These programs often include mammography, clinical breast exams, and self-breast exams to identify any abnormalities or signs of breast cancer. Implementing these programs has increased awareness and early detection of breast cancer cases, resulting in higher demand for effective therapeutics.
In addition, many advancements in diagnostic technologies have been witnessed across the globe. The National Library of Medicine states that early detection and precise diagnosis are essential for enhancing prognosis. Breast cancer assessment frequently makes use of radiographic imaging modalities such as digital mammography (DM), digital breast tomosynthesis (DBT), magnetic resonance imaging (MRI), ultrasound (US), and nuclear medicine procedures. Histopathology (HP) is the gold standard for determining the presence of cancer. Furthermore, using artificial intelligence (AI) technology to depict medical images quantitatively has significant potential for improving breast cancer segmentation, diagnosis, and prognosis. These technologies help healthcare providers identify the extent and characteristics of the tumor, allowing them to develop personalized treatment plans. Thus, the launch of diagnostic and screening programs, coupled with advancements in diagnostic technologies, contributes to the Asia Pacific breast cancer therapeutics market growth.
Asia Pacific Breast Cancer Therapeutics Market Overview
The breast cancer therapeutics market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market growth is attributed to factors including growing burden of breast cancers among women coupled with advancements in personalized medicine, immunotherapy, combination therapies, and drug delivery systems.
The breast cancer therapeutics market in China is projected to witness substantial growth in the coming years, owing to the rising prevalence of breast cancer, increasing aging population, lifestyle changes, and others. China accounted for 24% of cases with new diagnoses and 30% of cancer-related fatalities globally in 2020, as per CDC statistics published on April 14, 2023. Over the last three decades, the age-standardized incidence of breast cancer climbed from 17.07 per 100,000 in 1990 to 35.61 per 100,000 in 2019. Advancements in treatment options have played a crucial role in driving the demand for breast cancer therapeutics in China.
Also, out of 1 in 10 women in Japan will acquire breast cancer at some point. The pink ribbon campaign in October and other initiatives have raised awareness of the disease among Japanese people, including the importance of self-checks and other early detection methods that, when used, increase the survival rate to over 90%. The identification of typical risk variables, however, lags. Thus, the breast cancer therapeutics market in Japan is expected to grow significantly due to an aging population, treatment options, government initiatives and policies, high healthcare expenditure, rising awareness, and technological advancements.
Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Breast Cancer Therapeutics Market Segmentation
The Asia Pacific breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.
Based on drug therapy, the Asia Pacific breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.
In terms of breast cancer type, the Asia Pacific breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.
By distribution channel, the Asia Pacific breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.
Based on country, the Asia Pacific breast cancer therapeutics market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific breast cancer therapeutics market in 2022.
Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc and Amgen Inc are some of the leading companies operating in the Asia Pacific breast cancer therapeutics market.
Launch of Several Diagnostics and Screening Programs Fuels the Asia Pacific Breast Cancer Therapeutics Market
Advancements in personalized medicine, immunotherapy, combination therapies, drug delivery systems, liquid biopsies, AI, and patient-centric approaches are expected to shape the future of breast cancer treatment. These trends aim to improve treatment outcomes, reduce side effects, and enhance breast cancer patients overall quality of life.
Early disease detection plays a major role in improving patient outcomes and survival rates. Various organizations and healthcare providers are implementing screening programs to detect breast cancer at an initial stage when it is more treatable. The World Health Organization released a new Global Breast Cancer Initiative Framework in February 2013 that serves as a plan for fulfilling the goal of saving 2.5 million people from breast cancer by 2040. To achieve this, the new Framework, unveiled ahead of the World Cancer Day campaign, urges nations to follow the three pillars of health promotion for early detection, prompt diagnosis, and thorough management of breast cancer. These programs often include mammography, clinical breast exams, and self-breast exams to identify any abnormalities or signs of breast cancer. Implementing these programs has increased awareness and early detection of breast cancer cases, resulting in higher demand for effective therapeutics.
In addition, many advancements in diagnostic technologies have been witnessed across the globe. The National Library of Medicine states that early detection and precise diagnosis are essential for enhancing prognosis. Breast cancer assessment frequently makes use of radiographic imaging modalities such as digital mammography (DM), digital breast tomosynthesis (DBT), magnetic resonance imaging (MRI), ultrasound (US), and nuclear medicine procedures. Histopathology (HP) is the gold standard for determining the presence of cancer. Furthermore, using artificial intelligence (AI) technology to depict medical images quantitatively has significant potential for improving breast cancer segmentation, diagnosis, and prognosis. These technologies help healthcare providers identify the extent and characteristics of the tumor, allowing them to develop personalized treatment plans. Thus, the launch of diagnostic and screening programs, coupled with advancements in diagnostic technologies, contributes to the Asia Pacific breast cancer therapeutics market growth.
Asia Pacific Breast Cancer Therapeutics Market Overview
The breast cancer therapeutics market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market growth is attributed to factors including growing burden of breast cancers among women coupled with advancements in personalized medicine, immunotherapy, combination therapies, and drug delivery systems.
The breast cancer therapeutics market in China is projected to witness substantial growth in the coming years, owing to the rising prevalence of breast cancer, increasing aging population, lifestyle changes, and others. China accounted for 24% of cases with new diagnoses and 30% of cancer-related fatalities globally in 2020, as per CDC statistics published on April 14, 2023. Over the last three decades, the age-standardized incidence of breast cancer climbed from 17.07 per 100,000 in 1990 to 35.61 per 100,000 in 2019. Advancements in treatment options have played a crucial role in driving the demand for breast cancer therapeutics in China.
Also, out of 1 in 10 women in Japan will acquire breast cancer at some point. The pink ribbon campaign in October and other initiatives have raised awareness of the disease among Japanese people, including the importance of self-checks and other early detection methods that, when used, increase the survival rate to over 90%. The identification of typical risk variables, however, lags. Thus, the breast cancer therapeutics market in Japan is expected to grow significantly due to an aging population, treatment options, government initiatives and policies, high healthcare expenditure, rising awareness, and technological advancements.
Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Breast Cancer Therapeutics Market Segmentation
The Asia Pacific breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.
Based on drug therapy, the Asia Pacific breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.
In terms of breast cancer type, the Asia Pacific breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.
By distribution channel, the Asia Pacific breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.
Based on country, the Asia Pacific breast cancer therapeutics market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific breast cancer therapeutics market in 2022.
Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc and Amgen Inc are some of the leading companies operating in the Asia Pacific breast cancer therapeutics market.
1. INTRODUCTION
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. ASIA PACIFIC BREAST CANCER THERAPEUTICS MARKET - KEY INDUSTRY DYNAMICS
4.1 Key Market Drivers
4.1.1 Growing Burden of Breast Cancer
4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:
5. BREAST CANCER THERAPEUTICS MARKET - ASIA PACIFIC MARKET ANALYSIS
5.1 Asia Pacific Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
6. ASIA PACIFIC BREAST CANCER THERAPEUTICS MARKET - REVENUE AND FORECAST TO 2030 - BY DRUG THERAPY
6.1 Overview
6.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
6.3.1 Overview
6.3.2 Targeted Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Asia Pacific Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
6.4.1 Overview
6.4.2 Hormonal Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 Asia Pacific Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
6.5.1 Overview
6.5.2 Chemotherapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
6.6.1 Overview
6.6.2 Immunotherapy/ Biological Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. ASIA PACIFIC BREAST CANCER THERAPEUTICS MARKET - REVENUE AND FORECAST TO 2030 - BY BREAST CANCER TYPE
7.1 Overview
7.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
7.3.1 Overview
7.3.2 Hormone Receptor: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
7.4.1 Overview
7.4.2 HER2+: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
7.5.1 Overview
7.5.2 Triple-Negative Breast Cancer: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. ASIA PACIFIC BREAST CANCER THERAPEUTICS MARKET - REVENUE AND FORECAST TO 2030 - BY DISTRIBUTION CHANNEL
8.1 Overview
8.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
8.4.1 Overview
8.4.2 Drug Store and Retail Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. ASIA PACIFIC BREAST CANCER THERAPEUTICS MARKET -COUNTRY ANALYSIS
9.1 Asia Pacific Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
9.1.1 Overview
9.1.2 Asia Pacific Breast Cancer Therapeutics Market, Breakdown, by Country- Revenue (2022) (US$ Million)
9.1.3 Asia Pacific Breast Cancer Therapeutics Market, by Countries, 2022 and 2030 (%)
9.1.3.1 China
9.1.3.1.1 China Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.2 China: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.1 China: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.2 China: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.3 China: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.1.4 China: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.2 Japan
9.1.3.2.1 Japan Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.2 Japan: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.1 Japan: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.2 Japan: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.3 Japan: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.2.4 Japan: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.3 India
9.1.3.3.1 India Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.2 India: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.1 India: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.2 India: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.3 India: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.3.4 India: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.4 Australia
9.1.3.4.1 Australia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.4.2 Australia: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.1 Australia: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.2 Australia: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.3 Australia: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.4.4 Australia: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.5 South Korea
9.1.3.5.1 South Korea Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.5.2 South Korea: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.2.1 South Korea: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.2.2 South Korea: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.3 South Korea: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.5.4 South Korea: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.6 Rest of Asia Pacific
9.1.3.6.1 Rest of Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.6.2 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.2.1 Rest of Asia Pacific: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.2.2 Rest of Asia Pacific: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.3 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.6.4 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
10. BREAST CANCER THERAPEUTICS MARKET-INDUSTRY LANDSCAPE
10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. COMPANY PROFILES
11.1 Eli Lilly and Co
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eisai Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 AstraZeneca Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Pfizer Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Merck & Co Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Amgen Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. APPENDIX
12.1 About Us
12.2 Glossary of Terms
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. ASIA PACIFIC BREAST CANCER THERAPEUTICS MARKET - KEY INDUSTRY DYNAMICS
4.1 Key Market Drivers
4.1.1 Growing Burden of Breast Cancer
4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:
5. BREAST CANCER THERAPEUTICS MARKET - ASIA PACIFIC MARKET ANALYSIS
5.1 Asia Pacific Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
6. ASIA PACIFIC BREAST CANCER THERAPEUTICS MARKET - REVENUE AND FORECAST TO 2030 - BY DRUG THERAPY
6.1 Overview
6.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
6.3.1 Overview
6.3.2 Targeted Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Asia Pacific Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
6.4.1 Overview
6.4.2 Hormonal Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 Asia Pacific Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
6.5.1 Overview
6.5.2 Chemotherapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
6.6.1 Overview
6.6.2 Immunotherapy/ Biological Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. ASIA PACIFIC BREAST CANCER THERAPEUTICS MARKET - REVENUE AND FORECAST TO 2030 - BY BREAST CANCER TYPE
7.1 Overview
7.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
7.3.1 Overview
7.3.2 Hormone Receptor: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
7.4.1 Overview
7.4.2 HER2+: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
7.5.1 Overview
7.5.2 Triple-Negative Breast Cancer: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. ASIA PACIFIC BREAST CANCER THERAPEUTICS MARKET - REVENUE AND FORECAST TO 2030 - BY DISTRIBUTION CHANNEL
8.1 Overview
8.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
8.4.1 Overview
8.4.2 Drug Store and Retail Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. ASIA PACIFIC BREAST CANCER THERAPEUTICS MARKET -COUNTRY ANALYSIS
9.1 Asia Pacific Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
9.1.1 Overview
9.1.2 Asia Pacific Breast Cancer Therapeutics Market, Breakdown, by Country- Revenue (2022) (US$ Million)
9.1.3 Asia Pacific Breast Cancer Therapeutics Market, by Countries, 2022 and 2030 (%)
9.1.3.1 China
9.1.3.1.1 China Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.2 China: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.1 China: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.2 China: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.3 China: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.1.4 China: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.2 Japan
9.1.3.2.1 Japan Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.2 Japan: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.1 Japan: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.2 Japan: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.3 Japan: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.2.4 Japan: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.3 India
9.1.3.3.1 India Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.2 India: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.1 India: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.2 India: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.3 India: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.3.4 India: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.4 Australia
9.1.3.4.1 Australia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.4.2 Australia: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.1 Australia: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.2 Australia: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.3 Australia: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.4.4 Australia: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.5 South Korea
9.1.3.5.1 South Korea Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.5.2 South Korea: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.2.1 South Korea: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.2.2 South Korea: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.3 South Korea: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.5.4 South Korea: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.6 Rest of Asia Pacific
9.1.3.6.1 Rest of Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.6.2 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.2.1 Rest of Asia Pacific: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.2.2 Rest of Asia Pacific: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.3 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.6.4 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
10. BREAST CANCER THERAPEUTICS MARKET-INDUSTRY LANDSCAPE
10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. COMPANY PROFILES
11.1 Eli Lilly and Co
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eisai Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 AstraZeneca Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Pfizer Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Merck & Co Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Amgen Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. APPENDIX
12.1 About Us
12.2 Glossary of Terms
